Facilitation of specific tolerance induction in adult mice by RS-61443
- PMID: 1549852
- DOI: 10.1097/00007890-199203000-00020
Facilitation of specific tolerance induction in adult mice by RS-61443
Abstract
RS-61443 is an immunosuppressive agent that facilitates pancreatic islet allograft acceptance in two mouse strain combinations (BALB/c----CBA and C57Bl/6J----BALB/c). A remarkable feature of this agent is its ability to facilitate long-term graft acceptance after a short (30 days) period of treatment; following withdrawal of the agent 40-70% of islet allografts are maintained for an indefinite period. This long-term graft acceptance has been shown to result from specific tolerance induction in the recipient animal. The state of specific tolerance is an active rather than a passive form of tolerance, such as clonal deletion or anergy. Active tolerance induction is cyclosporine-sensitive, although cyclosporine enhances graft acceptance when used in combination therapy with RS-61443, this agent inhibits tolerance development under the influence of RS-61443.
Similar articles
-
Tolerance induction in adult mice: cyclosporine inhibits RS-61443-induced tolerance.Transplant Proc. 1991 Feb;23(1 Pt 1):733-4. Transplant Proc. 1991. PMID: 1990669 No abstract available.
-
Operational tolerance in nonvascularized transplant models induced by AR-C117977, a monocarboxylate transporter inhibitor.Transplantation. 2008 Oct 27;86(8):1135-8. doi: 10.1097/TP.0b013e318186b978. Transplantation. 2008. PMID: 18946353
-
Anti-LFA-1 therapy induces long-term islet allograft acceptance in the absence of IFN-gamma or IL-4.J Immunol. 2000 Apr 1;164(7):3627-34. doi: 10.4049/jimmunol.164.7.3627. J Immunol. 2000. PMID: 10725719
-
Transplantation tolerance by 1,25-dihydroxyvitamin D(3)-induced costimulation blockade.Transplant Proc. 2001 Feb-Mar;33(1-2):219-20. doi: 10.1016/s0041-1345(00)01981-3. Transplant Proc. 2001. PMID: 11266786 No abstract available.
-
Novel immunosuppressive agents in tolerance induction.Curr Drug Targets Cardiovasc Haematol Disord. 2002 Dec;2(2):97-103. doi: 10.2174/1568006023337592. Curr Drug Targets Cardiovasc Haematol Disord. 2002. PMID: 12769651 Review.
Cited by
-
Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes.Diabetes Care. 2010 Apr;33(4):826-32. doi: 10.2337/dc09-1349. Epub 2010 Jan 12. Diabetes Care. 2010. PMID: 20067954 Free PMC article. Clinical Trial.
-
Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.Drugs. 1996 Feb;51(2):278-98. doi: 10.2165/00003495-199651020-00007. Drugs. 1996. PMID: 8808168 Review.
-
The spectrum of action of new immunosuppressive drugs.Clin Exp Immunol. 1992 Aug;89(2):170-3. doi: 10.1111/j.1365-2249.1992.tb06927.x. Clin Exp Immunol. 1992. PMID: 1379130 Free PMC article. Review. No abstract available.
-
New immunosuppressive drugs: mechanistic insights and potential therapeutic advances.Immunol Rev. 1993 Dec;136:71-98. doi: 10.1111/j.1600-065x.1993.tb00655.x. Immunol Rev. 1993. PMID: 8132204 Free PMC article. Review.
-
Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches.Cell Mol Immunol. 2017 Feb;14(2):146-179. doi: 10.1038/cmi.2016.39. Epub 2016 Oct 10. Cell Mol Immunol. 2017. PMID: 27721455 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources